No abstract

Purpose: In this study, we aimed to evaluate the relative level of methylation of this gene in stool samples of colorectal cancer patients.Methods: In present study, stool samples were collected from 40 colorectal cancer patients and 40 healthy controls. After collecting the DNA of the samples, the extracts were treated by sulfite method and the methylation of the target site was evaluated by met-HRM method. Differences in methylation level of the two groups were evaluated by appropriate statistical tests. P value <0.05 was considered significant.Results: The relative methylation rate of the studied genes (IGFBP3 and TWIST1) in the stool samples was lower than that of the healthy groups and this difference was significant in the confidence interval (P< 0.0001 and P< 0.0025, respectively). Meanwhile, this genes has no significant association with clinical findings Conclusion: Our findings suggest that the IGFBP3 and TWIST1 methylation could be used as a diagnostic biomarker in colorectal cancer. However, it is better to do more studies on the level of protein.

No abstract

Background Colorectal cancer (CRC) is still considered one of the prevalent cancers worldwide. Investigation of potential biomarkers for early detection of CRC is essential for the effective management of patients using therapeutic strategies. Considering that, this study was aimed to examine the changes in lncRNA FOXD2-AS1 expression through colorectal tumorigenesis. Material and Methods Fifty CRC tumor tissues and fifty adjacent normal tissue samples were prepared and involved in the current study. Total RNA was extracted from the samples and then reverse transcribed to complementary DNA. Next, the expression levels of lncRNA FOXD2-AS1 were evaluated using real-time PCR in CRC samples compared to normal ones. Also, receiver operating characteristic curve (ROC) analysis was used to evaluate the diagnostic value of FOXD2-AS1 for CRC. Results The obtained results showed that the expression level of FOXD2-AS1 gene was significantly (p < 0.0001) up-regulated in tumor tissues compared to normal marginal tissues. Also, a significant correlation was observed between higher the expression of FOXD2-AS1and the differentiation of tumor cells. Furthermore, ROC curve analysis estimated an AUC value of 0.59 for FOXD2-AS1, suggesting its potential as a diagnostic target. Conclusion Taken together, the current study implied that tissue-specific upregulation of lncRNA FOXD2-AS1 might be appropriate diagnostic biomarkers for CRC. Nonetheless, m studies are needed to validate these results and further illustrate FOXD2-AS1 function through colorectal tumorigenesis.